Online citations, reference lists, and bibliographies.
← Back to Search

Species Differences In Ocular Pharmacokinetics And Pharmacological Activities Of Regorafenib And Pazopanib Eye‐drops Among Rats, Rabbits And Monkeys

Shinya Horita, M. Watanabe, Mai Katagiri, H. Nakamura, H. Haniuda, Tomoyuki Nakazato, Y. Kagawa
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Age‐related macular degeneration (AMD) is the leading cause of severe vision impairment in patients over the age of 60 years. Choroidal neovascularization (CNV) is the hallmark of neovascular AMD and vascular endothelial growth factor (VEGF) plays a causal role in the formation of CNV. Although regorafenib and pazopanib, small molecule VEGF receptor (VEGFR) inhibitors, were developed as eye‐drops, their efficacies were insufficient in clinical. In this study, we evaluated ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib after ocular instillation in multiple animal species. In rats, both regorafenib and pazopanib showed high enough concentrations in the posterior eye tissues to inhibit VEGFR. In laser‐induced rat CNV model, regorafenib showed clear reduction in CNV area. On the other hand, the concentrations of regorafenib and pazopanib in the posterior eye tissues were much lower after ocular instillation in rabbits and monkeys compared to those in rats. Pazopanib did not show any improvement in monkey model. Regorafenib was nano‐crystalized to improve its drug delivery to the posterior eye tissues. The nano‐crystalized formulation of regorafenib showed higher concentrations in the posterior segments in rabbits compared to its microcrystal suspension. From these studies, large interspecies differences were found in ocular delivery to the posterior segments after ocular instillation. Such large interspecies difference could be the reason for the insufficient efficacies of regorafenib and pazopanib in clinical studies. Nano‐crystallization was suggested to be one of the effective ways to overcome this issue.
This paper references
10.1167/iovs.09-4890
Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.
P. Lichtlen (2010)
10.1016/j.ophtha.2009.10.007
The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis.
R. Kawasaki (2010)
VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
E. Gragoudas (2004)
VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
JS Heier (2012)
10.1016/J.IJPHARM.2007.03.011
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
M. Kassem (2007)
10.1056/nejmc081470
[Age-related macular degeneration].
A. Ramé (2006)
10.1016/j.ophtha.2012.03.053
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
D. Martín (2012)
10.1056/nejmc063011
Ranibizumab in neovascular age-related macular degeneration
K. Eng (2006)
Scientific viewpoints in ocular toxicity assessment: departure from conventional practice
H Onodera (2013)
10.1097/ICU.0000000000000147
Current phase 1/2 research for neovascular age-related macular degeneration
Paula E Pecen (2015)
10.1517/14728214.2014.884559
Emerging treatments for wet age-related macular degeneration
A. G. Smith (2014)
10.2165/11589330-000000000-00000
Neovascular Age-Related Macular Degeneration
R. M. Schiffelers (2012)
10.1080/14728214.2017.1362390
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
Rehan Hussain (2017)
Food and Drug Administration, labeling information (Regorafenib), ht tps ://w w w. acces sdat a.fda.gov/drugs at fda_doc s/label/ 2018/20308 5s008 lbl
10.1001/archopht.122.4.564
Prevalence of age-related macular degeneration in the United States.
D. Friedman (2004)
10.1016/j.drudis.2017.01.003
The in vivo fate of nanocrystals.
Yi Lu (2017)
10.1111/J.1600-0420.2007.00885.X
Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
H. Sigurdsson (2007)
10.1076/opep.11.2.67.28158
2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies
D. Pascolini (2004)
10.1167/iovs.12-10169
Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.
S. Robbie (2013)
10.1002/JPS.2600630304
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
S. Chrai (1974)
10.1007/s13346-016-0292-0
Nanocrystal for ocular drug delivery: hope or hype
O. P. Sharma (2016)
10.1016/S0002-9440(10)64525-7
Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.
K. Spilsbury (2000)
ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
D. Brown (2006)
10.1002/JPS.2600651230
Mechanistic studies on transcorneal permeation of pilocarpine.
J. Sieg (1976)
Food and Drug Administration, labeling information (Pazopanib), ht tps ://w w w. acces sdat a.fda.gov/drugs at fda_doc s/label/ 2017/02246 5s024 s025l bl
10.1016/j.ejphar.2011.05.016
Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Y. Yafai (2011)
10.1001/ARCHOPHT.120.3.338
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
M. Krzystolik (2002)
Hydrocortisone Nanosuspensions for Ophthalmic Delivery : A Comparative Study between Microfluidic Nanoprecipitation and Wet Milling
W. Abdel-Mageed (2013)
MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration
P J Rosenfeld (2006)
10.1167/iovs.12-10473
Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit.
T. Iwase (2013)
Ocular Drug Delivery
B. Gilger (2016)
10.1111/J.1600-0420.2006.00736.X
Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.
W. Soliman (2006)
10.1001/archopht.126.7.946
Comparing pegaptanib and triamcinolone efficacy in the rat choroidal neovascularization model.
M. Criswell (2008)
10.1016/j.ophtha.2014.09.036
Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
K. Csaky (2015)
10.1001/archophthalmol.2011.210
Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates.
T. Nork (2011)
10.1016/S0140-6736(07)61104-0
Clinical update: new treatments for age-related macular degeneration
T. Wong (2007)
10.1016/j.ophtha.2016.10.036
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
R. Parikh (2017)
10.1056/NEJMoa1102673
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
D. Martín (2011)
10.1111/bcp.13502
Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers
T. Zimmermann (2018)
10.1056/NEJMOA062655
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
D. Brown (2006)
10.1056/NEJMOA042760
Pegaptanib for neovascular age-related macular degeneration.
E. Gragoudas (2004)
10.1016/j.ophtha.2012.09.006
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
J. Heier (2012)
From the Food and Drug Administration.
J. Samet (2002)
10.1001/ARCHOPHT.122.4.564
Prevalence of age-related macular degeneration in the United States.
P. D. Jong (2004)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar